中国肺癌杂志Issue(10)：734-740,7.DOI:10.3779/j.issn.1009-3419.2014.10.05
PD-1/PD-L1信号通路在非小细胞肺癌免疫逃逸及其治疗中的研究进展
Advances of PD-1/PD-L1 Signaling Pathway in Immune Escape and Treatment for Non-small Cell Lung Cancer
摘要
Abstract
Lung cancer is the leading cause of cancer-related mortality worldwide. Despiting the great progress on target agents, majority of people who do not harbor a mutation could not get beneift from them. Immunotherapy, through stimulating the body's immune system to improve the antitumor immunity effect, has been a new therapeutic method for non-small cell lung cancer (NSCLC). Study had been reported that immune checkpoint molecules, including programmed death-1 (PD-1)/PD-ligand (L) 1 axis, are closedly related with cancer generation and development, and play a key role on clinical signiifcance of NSCLC. Activation of PD-1/PD-L1 pathway contributes to tumor immune escape, and block PD-1/PD-L1 pathway can enhance endogenous antimuor immunity. Currently increasing clinical trials suggested that immune checkpoint inhibitors, including anti-PD-1 and anti-PD-L1 monoclonal antibodies turned out to be beneifcial and safe in NSCLC. Here, we provide a review on the progress of PD-1/PD-L1 pathway and immune checkpoint inhibitors in NSCLC.关键词
肺肿瘤/程序性死亡分子1/程序性死亡分子1配体/免疫治疗/调定点阻滞剂/免疫逃逸Key words
Lung neoplasms/Programmed death 1/Programmed death 1 ligand/Immuno-therapy/Checkpoint inhibitors/Immune escape引用本文复制引用
林城,陈雄,刘静南,黄于芳(综述),欧阳学农(审校)..PD-1/PD-L1信号通路在非小细胞肺癌免疫逃逸及其治疗中的研究进展[J].中国肺癌杂志,2014,(10):734-740,7.基金项目
本研究受国家自然科学基金项目（No.81274002）资助hTis paper was supported by the grant from the Natural Science Foundation of China (to Xuenong OU-YANG)(No.81274002) （to Xuenong OU-YANG）
